Surprisingly, changes in urinary glucose excretion following drug administration were more substantial in patients with MODY3 than in those with T2DM, contrary to the expectation that the drug effect would be attenuated in patients with MODY3, owing to the decreased SGLT2 expression. Here, SLC5A2 is linked to maturity-onset diabetes of the young type 3.